A pharmaceutical company engaged in the development and commercialization of treatments for rare diseases, specifically focusing on alopecia and alopecia areata, with 19 FDA-approved drugs.
0
Orphan Designations
19
FDA Approvals
Latest: OPDIVO QVANTIG (2024)
0
Active Trials
2
Rare Diseases
across 2 areas
0
News (30d)
Quiet
E.R. Squibb & Sons, L.L.C. is a company with 0 orphan drug designations across 2 rare diseases, including 19 FDA-approved therapies.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| alopecia | KENALOG-10 | Des.TrialAppr. |
| alopecia areata | KENALOG-10 | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/2
candidate diseases
0
avg importance: 0
0
affecting portfolio